UBE2C and hepatocellular carcinoma: Figure 3B suggested that increased expression of UBE2C indicated poor RFS in HCC (HR = 2.06, 95% CI = 1.47–2.87, logrank P = 1.6e-05). Upregulation of UBE2C was significantly linked to poor PFS in HCC (HR = 1.97, 95% CI = 1.47–2.66, logrank P = 4.8e-05) (Figure 3C). Moreover, high expression of UBE2C was markedly associated with unfavorable DSS of patients with HCC (HR = 2.57, 95% CI = 1.65–4.00, logrank P = 1.5e-05) (Figure 3D). As shown in Figure 4A–4C, high expression of UBE2C indicated poor prognosis in HCC but no statistical significance of UBE2C in adjacent normal tissues was observed.